A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) (NCT06659640)
InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN-6400 in Adult Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Clinical Trial Site — Birmingham, Alabama
- Clinical Trial Site — Cypress, California
- Clinical Trial Site — Gainesville, Florida
- Clinical Trial Site — Indianapolis, Indiana
- Clinical Trial Site — Boston, Massachusetts
- Clinical Trial Site — Rochester, Minnesota
- Clinical Trial Site — St Louis, Missouri
- Clinical Trial Site — Chapel Hill, North Carolina
- Clinical Trial Site — Camperdown,
- Clinical Trial Site — Parkville,
- Clinical Trial Site — Mount Royal,
- Clinical Trial Site — Toronto,
- Clinical Trial Site — Bordeaux,
- Clinical Trial Site — Bron,
- Clinical Trial Site — Homburg,
- Clinical Trial Site — L'Hospitalet de Llobregat,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hereditary Hemorrhagic Telangiectasia
- CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry) — Toronto, Ontario
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia — Boston, Massachusetts
- Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) — Los Angeles, California
- DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia — Camperdown, New South Wales
- Comprehensive HHT Outcomes Registry of the United States (CHORUS) — Birmingham, Alabama
Explore by condition: All Hereditary Hemorrhagic Telangiectasia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.